Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine Plus GemOx vs GemOx for Relapsed/Refractory PTCL
NCT06941688Phase 2Terminated
- Sponsor
- Seoul National University Hospital
- Start
- Nov 2020
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of decitabine in peripheral T-cell lymphoma (PTCL) (2 arms), sponsored by Seoul National University Hospital. Primary endpoint: Objective Response Rate. Started Nov 2020; status: terminated.
02
Drugs
decitabine
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT06941688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06941688.